SEC Filing - 6-K
(WorldNews Denmark)

gmab_Ex99_1_19Feb20 Exhibit 99.1 Innovating antibodies, improving lives Annual Report 2019 Genmab A/S CVR No. 21 02 38 84 Table of Contents Management`s Review Financial Statements Genmab In Short ................................... 4 - HuMax-IL8 ..................................... 40 - Camidanlumab tesirine (ADCT-301) ................ 41 - JNJ-61186372 .................................. 41 - JNJ-63709178 .................................. 41 - JNJ-64007957 .................................. 42 - JNJ-64407564 .................................. 42 - JNJ-67571244 .................................. 42 - JNJ-63898081 .................................. 43 - Lu AF82422...